Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs. Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation. To determine whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clinical follow-up who received either no adjuvant therapy or adjuvant tamoxifen therapy after breast cancer surgery. METHODS: AIB1 and HER-2 protein levels in tumors from 316 breast cancer patients were determined using western blot analysis. Molecular variables (e.g., expression of AIB1, ER, progesterone receptor, p53, Bcl-2), tumor characteristics, and patient outcome were assessed using Spearman rank correlation. Disease-free survival (DFS) curves were derived from Kaplan-Meier estimates, and the curves were compared by log-rank tests. The effect of AIB1 on DFS adjusted for other prognostic factors was assessed by multivariable analysis using the Cox proportional hazards model. All statistical tests were two-sided. RESULTS: High AIB1 expression in patients not receiving adjuvant tamoxifen therapy was associated with better prognosis and longer DFS (P =.018, log-rank test). In contrast, for patients who did receive tamoxifen therapy, high AIB1 expression was associated with worse DFS (P =.049, log-rank test), which is indicative of tamoxifen resistance. The test for interaction between AIB1 expression and tamoxifen therapy was statistically significant (P =.004). When expression of AIB1 and HER-2 were considered together, patients whose tumors expressed high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen therapy than all other patients combined (P =.002, log-rank test). CONCLUSIONS: The antitumor activity of tamoxifen in patients with breast cancer may be determined, in part, by tumor levels of AIB1 and HER-2. Thus, AIB1 may be an important diagnostic and therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“A recent report ( 34 ) suggests that AIB1 is an important modifier gene contributing to the high incidence of breast cancer in patients carrying BRCA1 mutations (35).”
BackgroundMethodResultInfluentialAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., Nakatani, Y., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80516-4 · Cited by 1,465
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., & Rosenfeld, M. G. (1997) · Nature · doi:10.1038/42652 · Cited by 1,283
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Bunone, G., Briand, P. A., Miksicek, R. J., & Picard, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00571.x · Cited by 986
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Self-citationSmith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660
Self-citationPietras, R. J., Arboleda, J., Dm, R., Wongvipat, N., Pegram, M. D., Ramos, L., Cm, G., Mg, P., Sliwkowski, M. X., & Dj, S. (1995) · PubMed · Cited by 603
RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
Li, H., Gomes, P. J., & Chen, J. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8479 · Cited by 581
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
Self-citationJackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. W., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.693 · Cited by 478
Le Goff, P., Montano, M. M., Schodin, D. J., & Katzenellenbogen, B. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41801-1 · Cited by 452
Ali, S., Metzger, D., Bornert, J. M., & Chambon, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05756.x · Cited by 448
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Bautista, S., Valles, H., Walker, R. L., Anzick, S. L., Zeillinger, R., Meltzer, P. S., & Theillet, C. G. (1998) · PubMed · Cited by 264
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase
Wu, R.-C., Qin, J., Hashimoto, Y., Wong, J., Xu, J., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3549-3561.2002 · Cited by 257
Self-citationAnalysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.
McInerney, E. M., Tsai, M. J., O'Malley, B. W., & Katzenellenbogen, B. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10069 · Cited by 256
BERGKVIST, L., ADAMI, H.-O., PERSSON, I., BERGSTROM, R., & KRUSEMO, B. U. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115328 · Cited by 240
Gapstur, S. M., Morrow, M., & Sellers, T. A. (1999) · JAMA · doi:10.1001/jama.281.22.2091 · Cited by 231
Bouras, T., Southey, M. C., & Venter, D. J. (2001) · PubMed · Cited by 196
Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor
Arnold, S. F. (1994) · Molecular Endocrinology · doi:10.1210/me.8.9.1208 · Cited by 176
Altered expression of estrogen receptor coregulators during human breast tumorigenesis.
Murphy, L. C., Simon, S. L., Parkes, A., Leygue, E., Dotzlaw, H., Snell, L., Troup, S., Adeyinka, A., & Watson, P. H. (2000) · PubMed · Cited by 168
List, H.-J., Lauritsen, K. J., Reiter, R., Powers, C., Wellstein, A., & Riegel, A. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102397200 · Cited by 148
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue
List, H.-J., Reiter, R., Singh, B., Wellstein, A., & Riegel, A. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1017910924390 · Cited by 148
Rebbeck, T. R., Wang, Y. L., Kantoff, P. W., Krithivas, K., Neuhausen, S. L., Godwin, A. K., Daly, M., Narod, S. A., Brunet, J., Vesprini, D., et al. (2001) · PubMed · Cited by 116
Regression models and life table (with discussion)
Cox (1972) · Medical Entomology and Zoology · Cited by 101
The role of HER-2 expression in predicting response to therapy in breast cancer.
MASS, R. D. (2000) · PubMed · Cited by 92
Jernström, H., Frenander, J., Fernö, M., & Olsson, H. L. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690543 · Cited by 82
Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer
Berns, E. M. J. J., van Staveren, I. L., Klijn, J. G. M., & Foekens, J. A. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005903226483 · Cited by 80
Interpreting and Integrating Risk Factors for Patients With Primary Breast Cancer
Clark, G. M. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003455 · Cited by 27
Self-citation
Cited by
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Self-citationCoregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Metadata
- Authors
- Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03-05
- Volume
- 95
- Issue
- 5
- Pages
- 353-361
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2109388713
- Cited by
- 786
- References
- 42
- FWCI
- 33.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.